Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
WESTLAKE VILLAGE, Calif., Oct. 01, 2017 -- MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) will host a conference call on Monday, October 2, 2017 to discuss Company developments at 9:00 AM (Eastern Time).
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 45747145. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4574 7145#. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818.661.5000
[email protected]
